Search

Displaying results 6311 - 6320 of 10000 in total
  1. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15715
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15716
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB15756
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza B virus B/Washington/02/2019 live (attenuated) antigen

    go.drugbank.com/drugs/DB15758
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16705
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16723
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16725
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome … EGT-301 is a gene therapy being investigated for Hunter Syndrome.

  9. Drug

    Lubazodone

    go.drugbank.com/drugs/DB09196
    Experimental

    Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was … It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.

  10. Drug

    2'-Deoxyuridine

    go.drugbank.com/drugs/DB02256
    Investigational

    An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. … Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. [PubChem]